GlycoMimetics (GLYC) Announces Dosing of First Patient in GMI-1271 Phase 1 for Multiple Myeloma
Tweet Send to a Friend
GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has dosed its first patient in a Phase 1 clinical trial of its novel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
